Market Cap 5.67B
Revenue (ttm) 376.57M
Net Income (ttm) -77.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -20.63%
Debt to Equity Ratio 0.03
Volume 930,356
Avg Vol 1,849,726
Day's Range N/A - N/A
Shares Out 62.27M
Stochastic %K 10%
Beta 2.11
Analysts Strong Sell
Price Target $87.56

Company Profile

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing,...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 800 719 0671
Address:
681 Gateway Boulevard, South San Francisco, United States
MOOSEN
MOOSEN Jul. 9 at 6:12 PM
$HROW $QURE $REPL $SLS $TWST THIS DUDE FOR REAL?
2 · Reply
alexpitti
alexpitti Jul. 9 at 5:49 PM
my best short ideas are $HROW $SLS $REPL $TWST and $QURE
1 · Reply
MaverikIT
MaverikIT Jul. 9 at 5:39 PM
@Jblack500 @No_Face_character @WAJeff @BustaCapital @cynicaloptimist @IsabellaDC $GH $NTRA $TWST ing away to Chubby Checker tune$
0 · Reply
handmedown1
handmedown1 Jul. 9 at 3:10 PM
$TWST $CRSP if only crspr had competent mgmt we would be on par with twist
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 9 at 3:01 PM
$SPCX crashed right after its IPO to $147. It's going under $100 first before ripping $1,000+ These 19 SPACE stocks will explode too: 1. $RKLB ~$87 Small-launch and satellite manufacturing filling the gaps Falcon can't serve efficiently. 2. $GILT ~$13 Satellite ground infrastructure scaling alongside enterprise and constellation broadband deployments. 3. $TWST ~$89 Synthetic DNA tools underpinning long-term space biology and life-support research. 4. $OUST ~$44 Digital lidar enabling autonomous docking, landing, and robotic space operations. To my subscribers and future subscribers: When the next bull run starts, this is the type of portfolio performance we are working to build again. Are you going to miss out again?
0 · Reply
MaverikIT
MaverikIT Jul. 9 at 2:16 PM
@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $TWST ing +5.49 - they love Chubby Checker tune$
1 · Reply
B2iDigital
B2iDigital Jul. 8 at 11:59 PM
eXoZymes (Nasdaq: $EXOZ ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale. Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes. In the webinar, Perryman also covered: • Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production • eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale • The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts Watch the full webinar: youtube.com/watch?v=OmH3TaaMT20&feature=youtu.be eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
EddieHayes
EddieHayes Jul. 8 at 11:13 PM
What $TWST actually does is fascinating. Short version: they manufacture DNA using a silicon chip platform. Think semiconductor manufacturing, but the product is genetic code. The thesis: DNA powers drug discovery, proteins, and biotech research. $TWST replaces slow traditional methods with high-throughput DNA manufacturing. Main businesses: Synthetic DNA Sequencing tools Antibody discovery DNA data storage Why it matters: AI drug discovery needs massive DNA testing. Approaching EBITDA breakeven. Gross margin expanded from 48% to 52% YoY. The simple view: $TWST is the picks-and-shovels play for the synthetic biology boom. They don’t make the drugs. They make the building blocks everyone needs.
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 10:14 PM
$TWST Current Stock Price: $89.41 Contracts to trade: $90.0 TWST Jul 17 2026 Call Entry: $3.00 Exit: $4.96 ROI: 65% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
howardlindzon
howardlindzon Jul. 8 at 6:19 PM
$TWST largest holding of $ARKG
2 · Reply
Latest News on TWST
Twist Bioscience files automatic mixed securities shelf

2026-06-18T20:15:47.000Z - 20 days ago

Twist Bioscience files automatic mixed securities shelf


Ozempic Linked To Lower Risk Of Violence In New Study

Jun 17, 2026, 11:45 AM EDT - 22 days ago

Ozempic Linked To Lower Risk Of Violence In New Study

AZN LLY NVO


Twist Bioscience initiated with a Buy at Canaccord

2026-06-15T09:45:05.000Z - 24 days ago

Twist Bioscience initiated with a Buy at Canaccord


Twist Bioscience Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 5 weeks ago

Twist Bioscience Slides: Corporate presentation


Twist Bioscience Transcript: Investor Day 2026

May 21, 2026, 2:00 PM EDT - 7 weeks ago

Twist Bioscience Transcript: Investor Day 2026


Twist Bioscience Slides: FY 2026

May 21, 2026, 2:00 PM EDT - 7 weeks ago

Twist Bioscience Slides: FY 2026


Twist Bioscience price target raised to $65 from $50 at Baird

2026-05-05T10:43:55.000Z - 2 months ago

Twist Bioscience price target raised to $65 from $50 at Baird


Twist Bioscience Earnings Call Transcript: Q2 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Twist Bioscience Earnings Call Transcript: Q2 2026


Twist Bioscience Earnings release: Q2 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Twist Bioscience Earnings release: Q2 2026


Twist Bioscience Slides: Q2 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Twist Bioscience Slides: Q2 2026


Twist Bioscience Quarterly report: Q2 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Twist Bioscience Quarterly report: Q2 2026


Twist Bioscience to Present at Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 5 months ago

Twist Bioscience to Present at Upcoming Investor Conferences


Twist Bioscience Slides: Corporate presentation

Feb 17, 2026, 7:00 AM EST - 5 months ago

Twist Bioscience Slides: Corporate presentation


Twist Bioscience Transcript: AGM 2026

Feb 5, 2026, 10:00 AM EST - 5 months ago

Twist Bioscience Transcript: AGM 2026


Twist Bioscience Earnings Call Transcript: Q1 2026

Feb 2, 2026, 8:00 AM EST - 5 months ago

Twist Bioscience Earnings Call Transcript: Q1 2026


Twist Bioscience Quarterly report: Q1 2026

Feb 2, 2026, 8:00 AM EST - 5 months ago

Twist Bioscience Quarterly report: Q1 2026


Twist Bioscience Earnings release: Q1 2026

Feb 2, 2026, 8:00 AM EST - 5 months ago

Twist Bioscience Earnings release: Q1 2026


Twist Bioscience Slides: Q1 2026

Feb 2, 2026, 8:00 AM EST - 5 months ago

Twist Bioscience Slides: Q1 2026


Twist Bioscience Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 6 months ago

Twist Bioscience Proxy statement: Proxy Filing


Can Twist Bioscience Drop More?

Nov 17, 2025, 9:25 AM EST - 8 months ago

Can Twist Bioscience Drop More?


Twist Bioscience Earnings Call Transcript: Q4 2025

Nov 14, 2025, 8:00 AM EST - 8 months ago

Twist Bioscience Earnings Call Transcript: Q4 2025


Twist Bioscience Annual report: Q4 2025

Nov 14, 2025, 8:00 AM EST - 8 months ago

Twist Bioscience Annual report: Q4 2025


Twist Bioscience Earnings release: Q4 2025

Nov 14, 2025, 8:00 AM EST - 8 months ago

Twist Bioscience Earnings release: Q4 2025


Twist Bioscience Slides: Q4 2025

Nov 14, 2025, 8:00 AM EST - 8 months ago

Twist Bioscience Slides: Q4 2025


Twist Bioscience Slides: FY 2025

Sep 9, 2025, 9:40 AM EDT - 10 months ago

Twist Bioscience Slides: FY 2025


Twist Bioscience Collaborates with Synthetic Design Lab

Sep 2, 2025, 8:00 AM EDT - 11 months ago

Twist Bioscience Collaborates with Synthetic Design Lab


Twist Bioscience Earnings Call Transcript: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings Call Transcript: Q3 2025


Twist Bioscience Quarterly report: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Quarterly report: Q3 2025


Twist Bioscience Earnings release: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings release: Q3 2025


Twist Bioscience Slides: Q3 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Slides: Q3 2025


Twist Bioscience Slides: Corporate Presentation

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Twist Bioscience Slides: Corporate Presentation


Twist Bioscience and Ginkgo Bioworks Revise Collaboration

May 8, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

DNA


Twist Bioscience Earnings Call Transcript: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings Call Transcript: Q2 2025


Twist Bioscience Quarterly report: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Quarterly report: Q2 2025


Twist Bioscience Earnings release: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Earnings release: Q2 2025


Twist Bioscience Slides: Q2 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Twist Bioscience Slides: Q2 2025


Twist Bioscience Earnings Call Transcript: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings Call Transcript: Q1 2025


Twist Bioscience Quarterly report: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Quarterly report: Q1 2025


Twist Bioscience Earnings release: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings release: Q1 2025


Twist Bioscience Slides: Q1 2025

Feb 3, 2025, 8:00 AM EST - 1 year ago

Twist Bioscience Slides: Q1 2025


Twist Bioscience Proxy statement: Proxy Filing

Jan 6, 2025, 7:00 AM EST - 1 year ago

Twist Bioscience Proxy statement: Proxy Filing


Twist Bioscience Proxy statement: Proxy Filing

Dec 26, 2024, 7:00 AM EST - 1 year ago

Twist Bioscience Proxy statement: Proxy Filing


Twist Bioscience Earnings Call Transcript: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings Call Transcript: Q4 2024


Twist Bioscience Annual report: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Annual report: Q4 2024


Twist Bioscience Earnings release: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Earnings release: Q4 2024


Twist Bioscience Slides: Q4 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Twist Bioscience Slides: Q4 2024


MOOSEN
MOOSEN Jul. 9 at 6:12 PM
$HROW $QURE $REPL $SLS $TWST THIS DUDE FOR REAL?
2 · Reply
alexpitti
alexpitti Jul. 9 at 5:49 PM
my best short ideas are $HROW $SLS $REPL $TWST and $QURE
1 · Reply
MaverikIT
MaverikIT Jul. 9 at 5:39 PM
@Jblack500 @No_Face_character @WAJeff @BustaCapital @cynicaloptimist @IsabellaDC $GH $NTRA $TWST ing away to Chubby Checker tune$
0 · Reply
handmedown1
handmedown1 Jul. 9 at 3:10 PM
$TWST $CRSP if only crspr had competent mgmt we would be on par with twist
0 · Reply
MarketMaestro1
MarketMaestro1 Jul. 9 at 3:01 PM
$SPCX crashed right after its IPO to $147. It's going under $100 first before ripping $1,000+ These 19 SPACE stocks will explode too: 1. $RKLB ~$87 Small-launch and satellite manufacturing filling the gaps Falcon can't serve efficiently. 2. $GILT ~$13 Satellite ground infrastructure scaling alongside enterprise and constellation broadband deployments. 3. $TWST ~$89 Synthetic DNA tools underpinning long-term space biology and life-support research. 4. $OUST ~$44 Digital lidar enabling autonomous docking, landing, and robotic space operations. To my subscribers and future subscribers: When the next bull run starts, this is the type of portfolio performance we are working to build again. Are you going to miss out again?
0 · Reply
MaverikIT
MaverikIT Jul. 9 at 2:16 PM
@Jblack500 @cynicaloptimist @BustaCapital @IsabellaDC @WAJeff @No_Face_character $TWST ing +5.49 - they love Chubby Checker tune$
1 · Reply
B2iDigital
B2iDigital Jul. 8 at 11:59 PM
eXoZymes (Nasdaq: $EXOZ ) makes its case for cell-free biomanufacturing, the approach it says sidesteps where whole-cell synthetic biology has repeatedly failed to scale. Whole-cell synthetic biology has a long record of stalling at scale. In a Webull webinar, eXoZymes Chief Commercial Officer Damien Perriman laid out why the company removed the cell from the equation entirely. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "Engineered cells have become a boulevard of broken dreams on Wall Street, and eXoZymes found a way to navigate around this problem," said Damien Perryman, Chief Commercial Officer of eXoZymes. In the webinar, Perryman also covered: • Cells evolved to survive, not to manufacture, so whole-cell systems carry biological noise, toxicity limits, and regulatory complexity into production • eXoZymes isolates the enzymes, engineers them with AI, and runs them outside the cell to produce target molecules cleanly and at scale • The result behaves more like precision chemistry than a biological production system, inspired by biology's own catalysts Watch the full webinar: youtube.com/watch?v=OmH3TaaMT20&feature=youtu.be eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
EddieHayes
EddieHayes Jul. 8 at 11:13 PM
What $TWST actually does is fascinating. Short version: they manufacture DNA using a silicon chip platform. Think semiconductor manufacturing, but the product is genetic code. The thesis: DNA powers drug discovery, proteins, and biotech research. $TWST replaces slow traditional methods with high-throughput DNA manufacturing. Main businesses: Synthetic DNA Sequencing tools Antibody discovery DNA data storage Why it matters: AI drug discovery needs massive DNA testing. Approaching EBITDA breakeven. Gross margin expanded from 48% to 52% YoY. The simple view: $TWST is the picks-and-shovels play for the synthetic biology boom. They don’t make the drugs. They make the building blocks everyone needs.
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 8 at 10:14 PM
$TWST Current Stock Price: $89.41 Contracts to trade: $90.0 TWST Jul 17 2026 Call Entry: $3.00 Exit: $4.96 ROI: 65% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
howardlindzon
howardlindzon Jul. 8 at 6:19 PM
$TWST largest holding of $ARKG
2 · Reply
11thestate
11thestate Jul. 7 at 2:16 PM
Bought $TWST Before the 20% Crash? Here's Everything You Need to Know About the $17M Settlement Payout Q: What happened? A: Investors claimed Twist Bioscience misled the market by overstating how automated, efficient, and profitable its DNA manufacturing business really was. A short-seller report later alleged the company relied on manual processes, had recurring product quality issues, and inflated its margins. After the report was published in 2022, $TWST dropped 20% in a single day. Q: Am I actually eligible? A: If you bought $TWST shares between 2018 and 2022, you're likely eligible. You don't need to still own the shares to file a claim. Q: When do payouts happen? A: Usually within 4–9 months after the claim deadline, depending on the court approval process and settlement administration. You can check if you’re eligible and claim your share: https://11th.com/cases/twist-investor-settlement
0 · Reply
RemitTekram
RemitTekram Jul. 7 at 12:28 PM
$PRCH $TWST $SLS I've made more in retirement the last couple of years than I made in my entire lucrative 34 year career. That just amazes me.
4 · Reply
anachartanalyst
anachartanalyst Jul. 6 at 6:02 PM
$TWST https://anachart.com/wp-content/uploads/2026/07/1783360932_soc-img.jpg
0 · Reply
Cap_00
Cap_00 Jul. 6 at 2:58 PM
$TWST f your downgrade evercore
0 · Reply
SonGoku
SonGoku Jul. 4 at 5:20 PM
Very nice gains this year $TWST
0 · Reply
Sihttegroftnod
Sihttegroftnod Jul. 3 at 3:30 AM
$TWST this and RXRX trip me out. So cool!
0 · Reply
MorganHoratio
MorganHoratio Jul. 2 at 11:29 PM
One of the strongest sectors outside of AI right now is Biotech. Drug Discovery $TWST Twist Bioscience $ABSI Absci $RXRX Recursion $ABCL AbCellera $NRIX Nurix Therapeutics Smart money is pivoting to the ultimate AI crossover: Drug Discovery & TechBio! This sector captures AI’s efficiency boom without the tech sector’s valuation bubble. DNA giant TWST is absolutely ripping, up over 200% this year to fresh historical highs on strong revenue growth. Protein degradation leader NRIX also just smashed 52-week highs. Alongside Nvidia-backed RXRX, ABSI, and ABCL, this sector is using AI algorithms to shatter traditional pharma limits. Can AI Biotech outpace pure tech in H2? Which ticker is your top play: TWST, ABSI, RXRX, ABCL, or NRIX? Drop your picks below! 👇
0 · Reply
DBRGLong
DBRGLong Jul. 2 at 4:53 PM
$TWST completely out of all remaining positions now at $104 earlier this morning, once the potential short squeeze volume appears to have dried up. Have now completely reinvested all proceeds into $ABT at an average cost of $92 a share. Looking forward to a great ride with $ABT through the upcoming soon to be reported earnings, & between now & year-end. Will look to re-enter TWST again some day down the road, once the price corrects & becomes more attractive. Much love to TWST for providing a tremendous well over 200%+ YTD return. Happy 4th of July to all in the meantime! 🥂
1 · Reply
SwingTraderPro1
SwingTraderPro1 Jul. 2 at 12:24 AM
While AI continues to dominate headlines, Biotechnology is quietly becoming one of the strongest sectors in the market.-2 Top 10 Biotechnology Stocks to Watch: $RXRX $BEAM $XENE $GH $TWST If liquidity starts broadening beyond mega-cap tech, biotech is one of the first areas that tends to catch bid early before it shows up in headlines. Head back to my profile to get the latest trading strategies and market analysis.
0 · Reply
DBRGLong
DBRGLong Jun. 30 at 8:50 PM
$TWST short squeeze appears to be underway for us. Next stop should be $110+? Let's see what happens 🥂
0 · Reply
anachartanalyst
anachartanalyst Jun. 29 at 6:02 PM
$TWST https://anachart.com/wp-content/uploads/2026/06/1782756112_soc-img.jpg
0 · Reply
RemitTekram
RemitTekram Jun. 29 at 12:01 PM
0 · Reply